The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.

The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.

The present invention involves novel crystal forms of Dabrafenib mesylate and preparation method thereof, wherein the novel crystal forms are more stable in water or an aqueous system, and have greater solubility and dissolution rate in water, thus having better stability and bioavailability compared with the existing crystal forms.

To provide an organic photoelectric conversion element whereby conversion efficiency is increased by morphology improvement in a power generation layer, and whereby short circuit current (Jsc) attenuation when irradiating light is simultaneously suppressed, and an organic solar cell using the same. An organic photoelectric conversion element having: a transparent first electrode; a power generation layer having a p-type organic semiconductor material and an n-type organic semiconductor material; and a second electrode, on a transparent substrate, in which the power generation layer is a bulk heterojunction power generation layer including the p-type organic semiconductor material and the n-type organic semiconductor material, and additionally includes a compound represented by either the following general formula (I) or general formula (II). ##STR00001##

To provide an organic photoelectric conversion element whereby conversion efficiency is increased by morphology improvement in a power generation layer, and whereby short circuit current (Jsc) attenuation when irradiating light is simultaneously suppressed, and an organic solar cell using the same. An organic photoelectric conversion element having: a transparent first electrode; a power generation layer having a p-type organic semiconductor material and an n-type organic semiconductor material; and a second electrode, on a transparent substrate, in which the power generation layer is a bulk heterojunction power generation layer including the p-type organic semiconductor material and the n-type organic semiconductor material, and additionally includes a compound represented by either the following general formula (I) or general formula (II). ##STR00001##

The present invention provides bumetanide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide analogs and methods for their use. These analogs are believed useful for the treatment and/or prophylaxis of conditions that involve the Na.sup.+K.sup.+Cl.sup. co-transporter or GABA.sub.A receptor.

The present disclosure provides pharmaceutical compositions comprising Gamma-glutamyl cycle inhibitors (GGCI) and certain pharmaceutically acceptable salts thereof, and methods of use.

The present invention provides bumetanide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide analogs and methods for their use. These analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na.sup.+K.sup.+Cl.sup. co-transporter or GABA.sub.A receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma. Huntington's Disease, insomnia, ischemia, migraine, migraine with aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.

The present invention provides bumetanide analogs and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these bumetanide analogs and methods for their use. These analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na.sup.+K.sup.+Cl.sup. co-transporter or GABA.sub.A receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma. Huntington's Disease, insomnia, ischemia, migraine, migraine with aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.

A method for producing (R)-1,1,3-trimethyl-4-aminoindane includes the following steps (A), (B), and (C). Step (A) is a step of optically resolving 1,1,3-trimethyl-4-aminoindane to obtain (R)-1,1,3-trimethyl-4-aminoindane and (S)-1,1,3-trimethyl-4-aminoindane, step (B) is a step of racemizing the (S)-1,1,3-trimethyl-4-aminoindane obtained in the step (A) or (C) to obtain 1,1,3-trimethyl-4-aminoindane, and step (C) is a step of optically resolving the 1,1,3-trimethyl-4-aminoindane obtained in the step (B) to obtain (R)-1,1,3-trimethyl-4-aminoindane and (S)-1,1,3-trimethyl-4-aminoindane.